Avian flu: Health and intellectual property

In the past several weeks, the specter of an avian flu pandemic has raised its ugly head again, with reports of new deaths in China, Indonesia and Vietnam. The first dead victims in South Asia were also reported. As nations, particularly in Asia, grapple with national logistical pressures, there have been parallel international discussions on the larger, longer-term implications for public health, innovation and intellectual property protection from issues arising from the pandemic threat, including new vaccines and cures.

The issues

These talks are held mainly in three intergovernmental fora: the World Health Organization (WHO) and the World Intellectual Property Organization (WIPO), both of which are part of the United Nations, and the World Trade Organization (WTO). The outcome of the talks would have an impact on future international action in combating widespread endemic sickness and deaths through better access to affordable drugs. They would also influence action in two other main areas: The first is government strategies on supporting costly efforts by the private sector to develop new effective drugs. The second is on some rethinking of the intellectual protection system which currently protects original R&D results so that the owners can recoup their investments and generate revenue.

Illness and death wait for no child, woman or man. Yet, despite the urgency and heavy socio-economic stakes, governments are taking their time to establish an international cooperation program to frame the three issues of public health, innovation and the intellectual property system. One reason is the intersection of three highly technical subjects. These have traditionally been handled by specialists in separate government agencies which are generally inward-looking. Those agencies are still struggling to deal with the internationalization of their subjects.

Another reason is that it is hard to question established beliefs and practices. For over 100 years, it was axiomatic that important innovation work flourished because of the protection guaranteed by national intellectual property laws. In other words, having exclusive rights for a limited period of time was a basic requirement for investment of human talent and financial resources in R&D, transforming the results into finished products and bringing them into the market place. Today, some people are calling on governments to reform the international intellectual property protection system on which national systems are based. The advocates argue for placing the public good ahead of the private profit motive, especially with regard to health as well as access to information and knowledge.

Slow pace and confused debate

At WHO, the two relevant bodies where such talks are held have long names: the Intergovernmental Meeting on Pandemic Influenza Preparedness (for sharing of influenza viruses and access to vaccines and other viruses); and the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property. It is hard, even in acronym-prone Singapore, to create suitable ones for these two bodies. Despite the urgency, each body has met only once in each of the last two years, and each is expected to meet again only once next year. In short, three meetings each in three years, with consultations in the intervening periods.

The slow pace is not helped by the fact that participation by developing countries - the ones most affected by the issues - has been sporadic and scant at best. The lack of attention is exacerbated by the fact that participating countries send different negotiators to the two bodies and treat the two bodies’ work as independent of each other, notwithstanding the many overlapping issues.

The Intergovernmental Meeting is mostly attended by health experts and diplomats, while the Committee i